Randomized controlled trial between conventional versus sutureless bioprostheses for aortic valve replacement: Impact of mini and full sternotomy access at 1-year follow-up.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 04 05 2022
revised: 13 07 2022
accepted: 04 08 2022
pubmed: 10 8 2022
medline: 12 10 2022
entrez: 9 8 2022
Statut: ppublish

Résumé

The present study is a sub-analysis of the multicenter, randomized PERSIST-AVR trial (PERceval Sutureless Implant versus Standard Aortic Valve Replacement) comparing the in-hospital and 1-year results of sutureless versus conventional stented bioprostheses in isolated surgical aortic valve replacement (SAVR) within two different surgical approaches: mini-sternotomy (MS) and full-sternotomy (FS). A total of 819 patients (per-protocol population) underwent preoperative randomization to sutureless or stented biological valve at 47 centers worldwide. Sub-analysis on isolated SAVR was performed. Results were compared between sutureless and stented within the two different surgical approaches. 285 patients were implanted with Perceval (67% in MS) and 293 with stented valves (65% in MS). Sutureless group showed significantly reduced surgical times both in FS and MS. In-hospital results show no differences between Perceval and stented valves in FS, while a lower incidence of new-onset of atrial fibrillation (3.7% vs 10.8%) with Perceval in MS. After 1-year, use of sutureless valve showed a significant reduction of MACCE (5.2% vs 10.8%), stroke rate (1.0% vs 5.4%), new-onset of atrial fibrillation (4.2% vs 11.4%) and re-hospitalizations (21.8 days vs 47.6 days), compared to stented valves but presented higher rate of pacemaker implantation (11% vs 1.6%). Sutureless bioprosthesis showed significantly reduced procedural times during isolated SAVR in both surgical approaches. Patients with sutureless valves and MS access showed also better 1-year outcome regarding MACCEs, stroke, re-hospitalization and new-onset atrial fibrillation, but presented a higher rate of permanent pacemaker implantation compared to patients with stented bioprosthesis.

Sections du résumé

BACKGROUND
The present study is a sub-analysis of the multicenter, randomized PERSIST-AVR trial (PERceval Sutureless Implant versus Standard Aortic Valve Replacement) comparing the in-hospital and 1-year results of sutureless versus conventional stented bioprostheses in isolated surgical aortic valve replacement (SAVR) within two different surgical approaches: mini-sternotomy (MS) and full-sternotomy (FS).
METHODS
A total of 819 patients (per-protocol population) underwent preoperative randomization to sutureless or stented biological valve at 47 centers worldwide. Sub-analysis on isolated SAVR was performed. Results were compared between sutureless and stented within the two different surgical approaches.
RESULTS
285 patients were implanted with Perceval (67% in MS) and 293 with stented valves (65% in MS). Sutureless group showed significantly reduced surgical times both in FS and MS. In-hospital results show no differences between Perceval and stented valves in FS, while a lower incidence of new-onset of atrial fibrillation (3.7% vs 10.8%) with Perceval in MS. After 1-year, use of sutureless valve showed a significant reduction of MACCE (5.2% vs 10.8%), stroke rate (1.0% vs 5.4%), new-onset of atrial fibrillation (4.2% vs 11.4%) and re-hospitalizations (21.8 days vs 47.6 days), compared to stented valves but presented higher rate of pacemaker implantation (11% vs 1.6%).
CONCLUSIONS
Sutureless bioprosthesis showed significantly reduced procedural times during isolated SAVR in both surgical approaches. Patients with sutureless valves and MS access showed also better 1-year outcome regarding MACCEs, stroke, re-hospitalization and new-onset atrial fibrillation, but presented a higher rate of permanent pacemaker implantation compared to patients with stented bioprosthesis.

Identifiants

pubmed: 35944771
pii: S0167-5273(22)01179-2
doi: 10.1016/j.ijcard.2022.08.012
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-61

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Theodor Fischlein (T)

Klinikum Nürnberg, Cardiovascular Center, Paracelsus Medical University, Nuremberg, Germany. Electronic address: theodor.fischlein@klinikum-nuernberg.de.

Elena Caporali (E)

Cardiology, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland; Cardiac Surgery, Istituto Cardiocentro Ticino, EOC, Lugano, Switzerland.

Thierry Folliguet (T)

Department of Cardiac Surgery, Hôpital Henri Mondor, Université Paris 12, Créteil, Paris, France.

Utz Kappert (U)

Herzzentrum Dresden GmbH Universitätsklinik, Dresden, Germany.

Bart Meuris (B)

UZ Gasthuisberg Leuven, University Hospital, Leuven, Belgium.

Malakh L Shrestha (ML)

Hannover Medical School, Hannover, Germany.

Eric E Roselli (EE)

Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.

Nikolaos Bonaros (N)

Medical University of Innsbruck, Innsbruck, Austria.

Olivier Fabre (O)

Lens Hospital and Bois Bernard Private Hospital, Lens, France.

Pierre Corbi (P)

Poitiers University Hospital, Poitiers, France.

Giovanni Troise (G)

Cardiac Surgery, Poliambulanza Foundation Hospital, Brescia, Italy.

Martin Andreas (M)

Medical University of Vienna, Vienna, Austria.

Frederic Pinaud (F)

Department of Cardiac Surgery, University Hospital Angers, Angers, France.

Steffen Pfeiffer (S)

Klinikum Nürnberg, Cardiovascular Center, Paracelsus Medical University, Nuremberg, Germany.

Sami Kueri (S)

University Heart Center Freiburg, Bad Krozingen, Germany.

Erwin Tan (E)

Catharina Ziekenhuis, Eindhoven, the Netherlands.

Pierre Voisine (P)

Division of Cardiac Surgery, Quebec Heart and Lung Institute, Quebec, Canada.

Evaldas Girdauskas (E)

University Heart Center Hamburg, Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg, Germany.

Filip Rega (F)

UZ Gasthuisberg Leuven, University Hospital, Leuven, Belgium.

Julio García-Puente (J)

University General Hospital Virgen de la Arrixaca, Murcia, Spain.

Roberto Lorusso (R)

Cardio-Thoracic Surgery Department, Heart and Vascular Center, Maastricht University Medical Center (MUMC+), Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH